RELATION BETWEEN PLASMA-CONCENTRATION AND CLINICAL EFFICACY AFTER SUBLINGUAL SINGLE DOSE APOMORPHINE IN PARKINSONS-DISEASE

被引：17
|
作者：
DURIF, F
JEANNEAU, E
SERREDEBEAUVAIS, F
DEFFOND, D
ESCHALIER, A
TOURNILHAC, M
机构：
[1] CHU CLERMONT FERRAND,NEUROL CLIN,F-63003 CLERMONT FERRAND,FRANCE
[2] CHU CLERMONT FERRAND,SERV PHARMACOL,F-63003 CLERMONT FERRAND,FRANCE
[3] CHU GRENOBLE,SERV PHARMACOL,F-38043 GRENOBLE,FRANCE
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 41卷 / 05期
关键词：
PARKINSONS DISEASE; APOMORPHINE; PHARMACOKINETICS; ADVERSE EFFECT; ON-OFF EFFECT;
D O I：
10.1007/BF00626377
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Five patients with Parkinson's disease were given a single sublingual dose of apomorphine in 3 mg tablets (2 patients received 18 mg and 3 patients took 39 mg). The therapeutic effect appeared within 33.0 min and lasted 137 min. There was a significant correlation between peak concentration, area under the curve, dose (mg/kg) and the duration of the therapeutic effect.
引用
收藏
页码：493 / 494
页数：2
相关论文
共 29 条
  • [1] RELATION BETWEEN CLINICAL EFFICACY AND PHARMACOKINETIC PARAMETERS AFTER SUBLINGUAL APOMORPHINE IN PARKINSONS-DISEASE
    DURIF, F
    PAIRE, M
    DEFFOND, D
    ESCHALIER, A
    DORDAIN, G
    TOURNILHAC, M
    LAVARENNE, J
    [J]. CLINICAL NEUROPHARMACOLOGY, 1993, 16 (02) : 157 - 166
  • [2] EFFICACY OF SUBLINGUAL APOMORPHINE IN PARKINSONS-DISEASE
    DURIF, F
    DEFFOND, D
    TOURNILHAC, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (12): : 1105 - 1105
  • [3] EFFICACY OF SUBLINGUAL APOMORPHINE IN IDIOPATHIC PARKINSONS-DISEASE
    DURIF, F
    SERRE, F
    DEFFOND, D
    ESCHALIER, A
    TOURNILHAC, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (02) : 528 - 529
  • [4] SUBLINGUAL APOMORPHINE IN PARKINSONS-DISEASE - A CLINICAL AND PHARMACOKINETIC STUDY
    MONTASTRUC, JL
    RASCOL, O
    SENARD, JM
    GUALANO, V
    BAGHERI, H
    HOUIN, G
    LEES, A
    RASCOL, A
    [J]. CLINICAL NEUROPHARMACOLOGY, 1991, 14 (05) : 432 - 437
  • [5] APOMORPHINE IN TREATMENT OF PARKINSONS-DISEASE - COMPARISON BETWEEN SUBCUTANEOUS AND SUBLINGUAL ROUTES
    DEFFOND, D
    DURIF, F
    TOURNILHAC, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (01): : 101 - 103
  • [6] PHARMACOKINETICS AND CLINICAL EFFICACY OF RECTAL APOMORPHINE IN PATIENTS WITH PARKINSONS-DISEASE - A STUDY OF 5 DIFFERENT SUPPOSITORIES
    VANLAAR, T
    JANSEN, ENH
    NEEF, C
    DANHOF, M
    ROOS, RAC
    [J]. MOVEMENT DISORDERS, 1995, 10 (04) : 433 - 439
  • [7] PHARMACOKINETICS OF APOMORPHINE IN PARKINSONS-DISEASE - PLASMA AND CEREBROSPINAL-FLUID LEVELS IN RELATION TO MOTOR-RESPONSES
    HOFSTEE, DJ
    NEEF, C
    VANLAAR, T
    JANSEN, ENH
    [J]. CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) : 45 - 52
  • [8] The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease
    Ondo, WG
    Hunter, C
    Vuong, KD
    Jankovic, J
    [J]. PARKINSONISM & RELATED DISORDERS, 2000, 6 (04) : 237 - 240
  • [9] COMPLEX DYSTONIA OF PARKINSONS-DISEASE - CLINICAL-FEATURES AND RELATION TO PLASMA LEVODOPA PROFILE
    MCHALE, DM
    SAGE, JI
    SONSALLA, PK
    VITAGLIANO, D
    [J]. CLINICAL NEUROPHARMACOLOGY, 1990, 13 (02) : 164 - 170
  • [10] SEVERE EVENING DYSKINESIAS IN ADVANCED PARKINSONS-DISEASE - CLINICAL DESCRIPTION, RELATION TO PLASMA LEVODOPA, AND TREATMENT
    ZIMMERMAN, TR
    SAGE, JI
    LANG, AE
    MARK, MH
    [J]. MOVEMENT DISORDERS, 1994, 9 (02) : 173 - 177
123